Mobile

A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymo...

Update Il y a 4 ans
Reference: EUCTR2009-017359-92

A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary objectives - To determine if afamelanotide can reduce the severity of PLE related pruritis.

Inclusion criteria

  • Polymorphic light eruption (PLE)

Links